menu
    • menu
    [{"orgOrder":0,"company":"Immunogen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Mirvetuximab Soravtansine","moa":"Tubulin","graph1":"Oncology","graph2":"Phase III","graph3":"Immunogen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immunogen \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Immunogen \/ Not Applicable"},{"orgOrder":0,"company":"Immunogen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Mirvetuximab Soravtansine","moa":"Tubulin","graph1":"Oncology","graph2":"Phase III","graph3":"Immunogen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immunogen \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Immunogen \/ Not Applicable"},{"orgOrder":0,"company":"Immunogen","sponsor":"Jefferies LLC","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Financing","leadProduct":"Mirvetuximab Soravtansine","moa":"Tubulin","graph1":"Oncology","graph2":"Phase III","graph3":"Immunogen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immunogen \/ Jefferies LLC","highestDevelopmentStatusID":"10","companyTruncated":"Immunogen \/ Jefferies LLC"},{"orgOrder":0,"company":"Immunogen","sponsor":"Hangzhou Huadong Medicine Group Kangrun Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Collaboration","leadProduct":"Mirvetuximab Soravtansine","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Immunogen","amount2":0.31,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.31,"dosageForm":"","sponsorNew":"Immunogen \/ Huadong Medicine","highestDevelopmentStatusID":"10","companyTruncated":"Immunogen \/ Huadong Medicine"},{"orgOrder":0,"company":"Immunogen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Mirvetuximab Soravtansine","moa":"Tubulin","graph1":"Oncology","graph2":"Phase III","graph3":"Immunogen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immunogen \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Immunogen \/ Not Applicable"},{"orgOrder":0,"company":"Immunogen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Mirvetuximab Soravtansine","moa":"Tubulin","graph1":"Oncology","graph2":"Phase III","graph3":"Immunogen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Immunogen \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Immunogen \/ Not Applicable"},{"orgOrder":0,"company":"Immunogen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Mirvetuximab Soravtansine","moa":"Tubulin","graph1":"Oncology","graph2":"Phase III","graph3":"Immunogen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Immunogen \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Immunogen \/ Not Applicable"},{"orgOrder":0,"company":"Immunogen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Mirvetuximab Soravtansine","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Immunogen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Immunogen \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Immunogen \/ Not Applicable"},{"orgOrder":0,"company":"Immunogen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Mirvetuximab Soravtansine","moa":"Folate receptor alpha","graph1":"Oncology","graph2":"Phase III","graph3":"Immunogen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Immunogen \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Immunogen \/ Not Applicable"},{"orgOrder":0,"company":"Immunogen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Mirvetuximab Soravtansine","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Immunogen","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Immunogen \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Immunogen \/ Not Applicable"},{"orgOrder":0,"company":"Immunogen","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Public Offering","leadProduct":"Mirvetuximab Soravtansine","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Immunogen","amount2":0.33000000000000002,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0.37,"dosageForm":"Injectable\/Injection","sponsorNew":"Immunogen \/ Jefferies","highestDevelopmentStatusID":"12","companyTruncated":"Immunogen \/ Jefferies"},{"orgOrder":0,"company":"Immunogen","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Public Offering","leadProduct":"Mirvetuximab Soravtansine","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Immunogen","amount2":0.37,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0.37,"dosageForm":"Injectable\/Injection","sponsorNew":"Immunogen \/ Jefferies","highestDevelopmentStatusID":"12","companyTruncated":"Immunogen \/ Jefferies"},{"orgOrder":0,"company":"Immunogen","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Collaboration","leadProduct":"Mirvetuximab Soravtansine","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Immunogen","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Immunogen \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"Immunogen \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Immunogen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Mirvetuximab Soravtansine","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Immunogen","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Immunogen \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Immunogen \/ Not Applicable"},{"orgOrder":0,"company":"Immunogen","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2024","type":"Acquisition","leadProduct":"Mirvetuximab Soravtansine","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Immunogen","amount2":10.1,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":10.1,"dosageForm":"Infusion","sponsorNew":"Immunogen \/ AbbVie Inc","highestDevelopmentStatusID":"12","companyTruncated":"Immunogen \/ AbbVie Inc"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Mirvetuximab Soravtansine","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AbbVie Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AbbVie Inc \/ Not Applicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Mirvetuximab Soravtansine","moa":"","graph1":"Technology","graph2":"Approved","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"AbbVie Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AbbVie Inc \/ Not Applicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Mirvetuximab Soravtansine","moa":"","graph1":"Technology","graph2":"Approved","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"AbbVie Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AbbVie Inc \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals for Mirvetuximab Soravtansine

    Menu

    Mirvetuximab Soravtansine

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            AbbVie Inc

                            U.S.A
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Mirvetuximab Soravtansine

                            Therapeutic Area : Oncology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            AbbVie Secures EU Approval for ELAHERE® in Platinum-Resistant Ovarian Cancer

                            Details : Elahere (mirvetuximab soravtansine) is a first-in-class antibody-drug conjugate (ADC) approved for folate receptor alpha (FRα) positive platinum-resistant ovarian cancer.

                            Brand Name : Elahere

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            November 18, 2024

                            Lead Product(s) : Mirvetuximab Soravtansine

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            Abbvie Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            AbbVie Inc

                            U.S.A
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Mirvetuximab Soravtansine

                            Therapeutic Area : Oncology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            AbbVie Receives Positive CHMP Opinion for Mirvetuximab Soravtansine in Ovarian Cancer

                            Details : Elahere (mirvetuximab soravtansine) is a first-in-class antibody-drug conjugate (ADC) approved for folate receptor alpha (FRα) positive platinum-resistant ovarian cancer.

                            Brand Name : Elahere

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            September 20, 2024

                            Lead Product(s) : Mirvetuximab Soravtansine

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            Abbvie Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            AbbVie Inc

                            U.S.A
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Mirvetuximab Soravtansine

                            Therapeutic Area : Oncology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            FDA Grants Full Approval for ELAHERE® for Certain Ovarian Cancer Patients

                            Details : Elahere (mirvetuximab soravtansine) is a first-in-class antibody-drug conjugate (ADC) approved for folate receptor alpha (FRα) positive platinum-resistant ovarian cancer.

                            Brand Name : Elahere

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            March 22, 2024

                            Lead Product(s) : Mirvetuximab Soravtansine

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            Abbvie Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Immunogen

                            U.S.A
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Mirvetuximab Soravtansine

                            Therapeutic Area : Oncology

                            Study Phase : Approved

                            Sponsor : AbbVie Inc

                            Deal Size : $10,100.0 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            AbbVie Completes Acquisition of ImmunoGen

                            Details : The acquisition accelerates AbbVie's presence in the solid tumor space by adding Elahere (mirvetuximab soravtansine-gynx), an ADC approved for FRα-positive platinum-resistant ovarian cancer.

                            Brand Name : Elahere

                            Molecule Type : Large molecule

                            Upfront Cash : $10,100.0 million

                            February 12, 2024

                            Lead Product(s) : Mirvetuximab Soravtansine

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved

                            Sponsor : AbbVie Inc

                            Deal Size : $10,100.0 million

                            Deal Type : Acquisition

                            Immunogen

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Immunogen

                            U.S.A
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Mirvetuximab Soravtansine

                            Therapeutic Area : Oncology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            ELAHERE® Shows Overall and Progression-Free Survival Benefit Regardless of Prior PARPi Exposure or Prior Line...

                            Details : Elahere (mirvetuximab soravtansine-gynx) is an ADC. The antibody is a chimeric IgG1 directed against folate receptor alpha and DM4, is a microtubule inhibitor attached to the antibody via a cleavable linker. It is being developed for FRα-positive platin...

                            Brand Name : Elahere

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            September 28, 2023

                            Lead Product(s) : Mirvetuximab Soravtansine

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            Immunogen

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Immunogen

                            U.S.A
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Mirvetuximab Soravtansine

                            Therapeutic Area : Oncology

                            Study Phase : Approved

                            Sponsor : Takeda Pharmaceutical

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            ImmunoGen Announces Collaboration with Takeda to Develop and Commercialize ELAHERE® in Japan

                            Details : Under the agreement, ImmunoGen has retained production rights and will supply product for development and commercial use in Japan and Takeda will receive license to develop and commercialize ELAHERE in Japan and is responsible for all regulatory filings ...

                            Brand Name : Elahere

                            Molecule Type : Large molecule

                            Upfront Cash : $34.0 million

                            August 28, 2023

                            Lead Product(s) : Mirvetuximab Soravtansine

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved

                            Sponsor : Takeda Pharmaceutical

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            Immunogen

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Immunogen

                            U.S.A
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Mirvetuximab Soravtansine

                            Therapeutic Area : Oncology

                            Study Phase : Approved

                            Sponsor : Jefferies

                            Deal Size : $373.8 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            ImmunoGen Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additio...

                            Details : ImmunoGen intends to use the proceeds to fund its operations, including global commercialization activities, supply of ELAHERE® (mirvetuximab soravtansine-gynx) drug product, pipeline research and development activities, business development, and capita...

                            Brand Name : Elahere

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            May 09, 2023

                            Lead Product(s) : Mirvetuximab Soravtansine

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved

                            Sponsor : Jefferies

                            Deal Size : $373.8 million

                            Deal Type : Public Offering

                            Immunogen

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Immunogen

                            U.S.A
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Mirvetuximab Soravtansine

                            Therapeutic Area : Oncology

                            Study Phase : Approved

                            Sponsor : Jefferies

                            Deal Size : $325.0 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            ImmunoGen Announces Pricing of Upsized Public Offering of Common Stock

                            Details : ImmunoGen intends to use the net proceeds to fund its operations, including, but not limited to, global commercialization activities, supply of ELAHERE® (mirvetuximab soravtansine-gynx) drug product, clinical trial activities, pipeline research and deve...

                            Brand Name : Elahere

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            May 04, 2023

                            Lead Product(s) : Mirvetuximab Soravtansine

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved

                            Sponsor : Jefferies

                            Deal Size : $325.0 million

                            Deal Type : Public Offering

                            Immunogen

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Immunogen

                            U.S.A
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Mirvetuximab Soravtansine

                            Therapeutic Area : Oncology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            ELAHERE® Demonstrates Overall Survival Benefit in the Phase 3 MIRASOL Trial in Patients with FRα-Positive Pl...

                            Details : Elahere (mirvetuximab soravtansine-gynx) is an ADC. The antibody is a chimeric IgG1 directed against folate receptor alpha and DM4, is a microtubule inhibitor attached to the antibody via a cleavable linker. It is being developed for FRα-positive platin...

                            Brand Name : Elahere

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            May 03, 2023

                            Lead Product(s) : Mirvetuximab Soravtansine

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            Immunogen

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Immunogen

                            U.S.A
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Mirvetuximab Soravtansine

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            ImmunoGen Presents Additional Analyses Evaluating Mirvetuximab Soravtansine in Ovarian Cancer at ESMO

                            Details : In the intent-to-treat population, statistically significant improvement in number of patients achieving 15-point improvement in gastrointestinal symptoms was observed at week 8/9 in patients treated with IMGN853 (mirvetuximab) versus chemotherapy (31.7%...

                            Brand Name : IMGN853

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            September 11, 2022

                            Lead Product(s) : Mirvetuximab Soravtansine

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            Immunogen

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth